Royalty Pharma (RPRX) director Bonnie Bassler awarded 4,545 RSUs, raising holdings to 78,492 shares

Rhea-AI Filing Summary

Bassler Bonnie L reported acquisition or exercise transactions in this Form 4 filing.

Royalty Pharma plc director Bonnie L. Bassler received an equity award of 4,545 Class A Ordinary Shares in the form of restricted stock units. These units were granted at no cash cost and increase her directly held position to 78,492 shares.

The award was granted under Royalty Pharma’s 2020 Independent Director Equity Incentive Plan and is generally scheduled to vest 100% on the earlier of the one-year anniversary of the grant date or the next annual shareholder meeting, subject to plan and award terms. This is a routine, compensation-related grant rather than an open-market share purchase or sale.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Bassler Bonnie L

Role null

Type	Security	Shares	Price	Value
Grant/Award	Class A Ordinary Shares	4,545	$0.00	--

Holdings After Transaction: Class A Ordinary Shares — 78,492 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

RSU grant: 4,545 shares Holdings after grant: 78,492 shares Grant price: $0.0000 per share +1 more

4 metrics

RSU grant 4,545 shares Restricted stock unit award to director on June 5, 2026

Holdings after grant 78,492 shares Class A Ordinary Shares held directly after transaction

Grant price $0.0000 per share Equity award granted at no cash cost to director

Vesting schedule 100% cliff vesting Earlier of one-year from grant or next annual shareholder meeting

Key Terms

restricted stock units, 2020 Independent Director Equity Incentive Plan, vest 100%, annual meeting of the Issuer's shareholders

4 terms

restricted stock units financial

"Reflects an award of restricted stock units under the Issuer's 2020 Independent Director Equity Incentive Plan"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

2020 Independent Director Equity Incentive Plan financial

"under the Issuer's 2020 Independent Director Equity Incentive Plan (the "Plan")"

vest 100% financial

"generally scheduled to vest 100% on the earlier of (i) the one-year anniversary"

annual meeting of the Issuer's shareholders financial

"the date of the annual meeting of the Issuer's shareholders in the first calendar year"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bassler Bonnie L

(Last) (First) (Middle)

C/O ROYALTY PHARMA PLC

110 E. 59TH STREET

(Street)

NEW YORK NEW YORK 10022

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Royalty Pharma plc [ RPRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/05/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Ordinary Shares	06/05/2026		A		4,545(1)	A	$0	78,492	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Reflects an award of restricted stock units under the Issuer's 2020 Independent Director Equity Incentive Plan (the "Plan") that is generally scheduled to vest 100% on the earlier of (i) the one-year anniversary of the grant date and (ii) the date of the annual meeting of the Issuer's shareholders in the first calendar year following the grant date, subject to the terms of the Plan and the applicable award agreement thereunder.

Remarks:

	/s/ Sean Weisberg, as Attorney-in-Fact for Bonnie L. Bassler	06/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Royalty Pharma (RPRX) director Bonnie L. Bassler report in this Form 4?

Bonnie L. Bassler reported receiving 4,545 Class A Ordinary Shares as a restricted stock unit award. The grant is part of director compensation and did not involve an open-market purchase or sale, so it reflects equity-based pay rather than trading activity.

How many Royalty Pharma (RPRX) shares does Bonnie L. Bassler hold after this grant?

After the grant, Bonnie L. Bassler holds 78,492 Class A Ordinary Shares directly. This total includes the newly awarded 4,545 restricted stock units, which are subject to vesting conditions under the company’s 2020 Independent Director Equity Incentive Plan.

What are the vesting terms for Bonnie L. Bassler’s new Royalty Pharma restricted stock units?

The 4,545 restricted stock units are generally scheduled to vest 100% on the earlier of the one-year anniversary of the grant date or the date of the next annual shareholder meeting, assuming continued service and compliance with the plan and award agreement terms.

Did Bonnie L. Bassler buy or sell Royalty Pharma (RPRX) shares on the open market?

No, Bonnie L. Bassler did not buy or sell shares on the open market in this filing. She received 4,545 shares as a restricted stock unit award, granted at no cash cost as part of her compensation as an independent director.

Under which plan were the new Royalty Pharma shares granted to Bonnie L. Bassler?

The award was granted under Royalty Pharma’s 2020 Independent Director Equity Incentive Plan. This plan provides equity-based compensation to independent directors, with specific vesting schedules and conditions detailed in the plan and individual award agreements.

What does a transaction code "A" mean in Bonnie L. Bassler’s Royalty Pharma Form 4?

Transaction code “A” indicates a grant, award, or other acquisition of securities. In this case, it reflects Bonnie L. Bassler’s receipt of 4,545 restricted stock units as director compensation, not an open-market purchase at a stated price per share.